Saturday, October 26, 2019 3:15:09 AM
Clearly I'm no expert, but don't the dendritic cells vary depending on the cancer being fought. If they don't, it would seem like a person could go through the procedure once in their life, and have a vaccine that could be used on any cancer provided what they did was properly preserved.
I was of the belief that the vaccine is so personal that it was specific to the cancer being fought, that's why I reasoned that if in fact the cancer morphed over time, so would the dendritic cells.
I believe the more we learn about cancer the more we realize how complex it really is. I believe over time that drugs that are individualized to not just cancer, but many diseases will prove much more effective than drugs made in mass. Automation will bring down the cost of making such drugs, and because of their effectiveness, they'll prove to be cheaper in the long run, but not necessarily in the drug cost itself. What I'm suggesting should be included is the cost of down time of the people being treated. If a personalized drug achieved a sufficient cure for a person to return to work in a week, whereas conventional meds would take a month, the productive time of the individual should be considered as part of the costs. Today, accountants often tell Doctors what drugs they must use initially due to price, if those drugs fail, they permit the more expensive product to be used. No consideration is given to the time lost if the treatment time with the cheaper product takes longer to achieve it's goal. Certainly not all time is lost, but I don't believe people working while suffering can be as productive as when healthy. I'm a believer that Doctors, not accountants and attorneys, are who should suggest the course of treatment and insurance should pay for what the Doctors suggest is best. I believe if you took the bulk of the accountants and attorneys out of healthcare, costs would go down dramatically.
Gary
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM